Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 24;23(1):317.
doi: 10.1186/s12872-023-03285-w.

HMGCR gene polymorphism is associated with residual cholesterol risk in premature triple-vessel disease patients treated with moderate-intensity statins

Jiawen Li  1 , Xiaofang Tang  1 , Jingjing Xu  1 , Ru Liu  1 , Lin Jiang  1 , Lianjun Xu  1 , Jian Tian  1 , Xinxing Feng  1 , Yajie Wu  1 , Yin Zhang  1 , Dong Wang  1 , Kai Sun  1 , Bo Xu  1 , Wei Zhao  1 , Rutai Hui  1 , Runlin Gao  1 , Lei Song  2 , Jinqing Yuan  3 , Xueyan Zhao  4
Affiliations

HMGCR gene polymorphism is associated with residual cholesterol risk in premature triple-vessel disease patients treated with moderate-intensity statins

Jiawen Li et al. BMC Cardiovasc Disord. .

Abstract

Background: To investigate the association of HMGCR and NPC1L1 gene polymorphisms with residual cholesterol risk (RCR) in patients with premature triple-vessel disease (PTVD).

Methods: Three SNPs within HMGCR including rs12916, rs2303151, and rs4629571, and four SNPs within NPC1L1 including rs11763759, rs4720470, rs2072183, and rs2073547 were genotyped. RCR was defined as achieved low-density lipoprotein cholesterol (LDL-C) concentrations after statins higher than 1.8 mmol/L (70 mg/dL).

Results: Finally, a total of 609 PTVD patients treated with moderate-intensity statins were included who were divided into two groups: non-RCR group (n = 88) and RCR group (n = 521) according to LDL-C concentrations. Multivariate logistic regression showed the homozygotes for the minor allele of rs12916 within HMGCR gene (CC) were associated with a 2.08 times higher risk of RCR in recessive model [odds ratio (OR): 2.08, 95% confidence interval (CI): 1.16-3.75]. In codominant model, the individuals homozygous for the minor allele of rs12916 (CC) were associated with a 2.26 times higher risk of RCR (OR: 2.26, 95% CI: 1.16-4.43) while the heterozygous individuals (CT) were not, compared with the individuals homozygous for the major allele of rs12916 (TT). There was no significant association between the SNPs within NPC1L1 gene and RCR in various models.

Conclusions: We first reported that the variant homozygous CC of rs12916 within HMGCR gene may incur a significantly higher risk of RCR in PTVD patients treated with statins, providing new insights into early individualized guidance of precise lipid-lowering treatment.

Keywords: Gene polymorphisms; Low-density lipoprotein cholesterol; Premature triple-vessel disease; Residual cholesterol risk.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Patient Flow Chart DNA, deoxyribonucleic acid; LDL-C, low-density lipoprotein cholesterol; SNPs, single nucleotide polymorphisms; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; NPC1L1, Niemann-Pick C1-like 1
Fig. 2
Fig. 2
Logistic regression analysis between HMGCR and NPCL1L gene polymorphisms and residual cholesterol risk HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; NPC1L1, Niemann-Pick C1-like 1; OR, odds ratio; CI, confidential interval
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Report on Cardiovascular Health and Diseases in China. 2021: An Updated Summary. Biomed Environ Sci 2022, 35(7):573–603. - PubMed
    1. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90. doi: 10.1016/S0140-6736(12)60367-5. - DOI - PMC - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. - PMC - PubMed
    1. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E. Benefit of adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in patients with Versus without Diabetes Mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin Efficacy International Trial) Circulation. 2018;137(15):1571–82. doi: 10.1161/CIRCULATIONAHA.117.030950. - DOI - PubMed
    1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical Outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–22. doi: 10.1056/NEJMoa1615664. - DOI - PubMed

Publication types

MeSH terms

Substances

-